IMPAX Laboratories, Inc. Announces Litigation Against Shire Laboratories Relating to Supply of Generic Adderall XR(R)

HAYWARD, Calif.--(BUSINESS WIRE)--Impax Laboratories, Inc. (NASDAQ: IPXL) today announced that it has initiated litigation against Shire LLC and Shire Laboratories, Inc. (“Shire”) in order to resolve recent and recurring supply issues of its authorized generic version of Adderall XR®. The Company is seeking to compel Shire to deliver duly ordered amounts of product under the parties’ Settlement Agreement and License and Distribution Agreements.

MORE ON THIS TOPIC